Novocure
US-based Novocure Limited is a global oncology firm innovating cancer treatment technologies.
Founded
2000US-based Novocure Limited is a global oncology firm innovating cancer treatment technologies.
Founded in Portsmouth, United States, Novocure Limited is a pioneering oncology company dedicated to developing innovative cancer treatment technologies. The company's core mission is to extend survival rates for cancer patients through novel therapeutic approaches. Novocure's primary product is its Tumor Treating Fields (TTFields) therapy, a groundbreaking treatment modality that uses electric fields to disrupt cancer cell division. The company serves the global healthcare market, focusing on providing advanced solutions for various types of cancer.
Notable figures associated with Novocure include prominent researchers and medical professionals who contribute to its cutting-edge clinical trials and technological advancements. The company has received significant investment from leading healthcare investors, bolstering its research and development efforts. Key achievements include positive clinical trial results presented at major oncology conferences such as the American Society of Clinical Oncology (ASCO) Annual Meeting. Novocure's impact is evidenced by its innovative contributions to cancer treatment, offering new hope and improved outcomes for patients worldwide.
Companies similar to Novocure include Clovis Oncology, Traws Pharma, Verastem and G1 Therapeutics.
Novocure was founded in 2000.
Novocure's headquarters is located in Portsmouth, NH, US.
Novocure's most recent funding round was for $150M (USD) in November 2020.
As of Nov 9, 2020, Novocure has disclosed funding of $903.5M (USD). Undisclosed round amounts are excluded.
Novocure has 1,167 employees as of Feb 6, 2024.
G1 Therapeutics
g1therapeutics.com
